 In 1998, the "New England Journal of Medicine" published a paper by Olivieri and seven other authors, with further study results suggesting that deferiprone led to progressive hepatic fibrosis.Olivieri's scientific findings, which sparked the controversy, have been challenged on the basis of data from clinical trials conducted by Apotex.Deferiprone is approved for use in over 50 countries, but not in Canada.